# US 2001/0022973 A1 · Pharmaceutical composition for piperidinoalkanol compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0022973 A1
- Document ID: US20010022973A1
- Status: Published application
- Kind: A1
- Application number: 09/845,966
- Filed: 2001-04-30
- Published: 2001-09-20
- Earliest claimed: 1995-02-28
- Inventors: Thomas T. Ortyl; Paul F. Skultety; Kristen C. Mitchell; Deepak S. Phadke; Faraneh Attarchi; Marquerite L. Pierce; Aaron W. Schoeneman; Joseph M. Schnitz
- Web page: https://patentgrep.com/patent/US20010022973A1

## CPC

- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4858: {Organic compounds}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/08: Bronchodilators
- A61P 17/04: Antipruritics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.

## Claims

### Claim 1

A pharmaceutical composition comprising,
a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof wherein said piperidinoalkanol compound has a particle surface area of greater than about 1.0 m2/g; and
b) at least one inert ingredient.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1 wherein the inert ingredient is a disintegrant.

### Claim 3

A pharmaceutical composition in solid unit dosage form, comprising;
a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and
b) at least one inert ingredient.

### Claim 4 (depends on 3)

The pharmaceutical composition in solid unit dosage form according to claim 3 wherein the inert ingredient is a disintegrant.

### Claim 5 (depends on 3)

The pharmaceutical composition in solid unit dosage form according to claim 3, wherein said piperidinoalkanol compound is of the formula 10
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof.

### Claim 6 (depends on 5)

The pharmaceutical composition in solid unit dosage form according to claim 5, wherein X is zero.

### Claim 7 (depends on 5)

The pharmaceutical composition in solid unit dosage form according to claim 5, wherein at least one inert ingredient is selected from the group consisting of croscarmellose sodium, lactose, microcrystalline cellulose, pregelatinized starch, gelatin, calcium carbonate, magnesium stearate and sodium starch glycolate.

### Claim 8 (depends on 7)

The pharmaceutical composition in solid unit dosage form according to claim 7 wherein said inert ingredients comprise croscarmellose sodium, lactose, microcrystalline cellulose, pregelatinized starch and gelatin.

### Claim 9 (depends on 8)

The pharmaceutical composition in solid unit dosage form according to claim 8 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch and gelatin are present in amounts of about 1% to about 10%, 20% to about 85%, 20% to about 85%, 1% to about 30% and 1% to about 15%, respectively, by weight of the composition.

### Claim 10 (depends on 8)

The pharmaceutical composition in solid unit dosage form according to claim 8 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch and gelatin are present in amounts of about 4.8%, 33.8%, 33.8%, 9.6% and 3.5%, respectively, by weight of the composition.

### Claim 11 (depends on 7)

The pharmaceutical composition in solid unit dosage form according to claim 7 wherein said inert ingredients comprise microcrystalline cellulose, pregelatinized starch, gelatin, magnesium stearate, calcium carbonate and sodium starch glycolate.

### Claim 12 (depends on 11)

The pharmaceutical composition in solid unit dosage form according to claim 11 wherein microcrystalline cellulose, pregelatinized starch, gelatin, magnesium stearate, calcium carbonate and sodium starch glycolate are present in amounts of about 20% to about 85%, 5% to about 50%, 1% to about 15%, 0.05% to about 3%, 5% to about 50% and 1% to about 15%, respectively, by weight of the composition.

### Claim 13 (depends on 11)

The pharmaceutical composition in solid unit dosage form according to claim 11 wherein microcrystalline cellulose, pregelatinized starch, gelatin, magnesium stearate, calcium carbonate and sodium starch glycolate are present in amounts of about 34.9%, 29.4%, 3.3%, 0.5%, 15.6%, 5.6%, respectively, by weight of the composition.

### Claim 14 (depends on 7)

The pharmaceutical composition in solid unit dosage form according to claim 7 wherein said inert ingredients comprise croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate.

### Claim 15 (depends on 14)

The pharmaceutical composition in solid unit dosage form according to claim 14 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate are present in amounts of about 1% to about 10%, 20% to about 85%, 20% to about 85%, 1% to about 30%, 1% to about 15% and 0.05% to about 3.0%, respectively, by weight of the composition.

### Claim 16 (depends on 14)

The pharmaceutical composition in solid unit dosage form according to claim 14 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate are present in amounts of about 4.8%, 33.7%, 33.7%, 9.6%, 3.5% and 0.5%, respectively, by weight of the composition.

### Claim 17 (depends on 14)

The pharmaceutical composition in solid unit dosage form according to claim 14 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate are present in amounts of about 4.8%, 25.7%, 25.7%, 9.6%, 3.5% and 0.75%, respectively, by weight of the composition.

### Claim 18 (depends on 7)

The pharmaceutical composition in solid unit dosage form according to claim 7 wherein said inert ingredients comprise microcrystalline cellulose, pregelatinized starch, magnesium stearate, calcium carbonate and sodium starch glycolate.

### Claim 19 (depends on 18)

The pharmaceutical composition in solid unit dosage form according to claim 18 wherein microcrystalline cellulose, pregelatinized starch, magnesium stearate, calcium carbonate and sodium starch glycolate are present in amounts of about 20% to about 85%, 5% to about 50%, 0.05% to about 3%, 5% to about 50% and 1% to about 15%, respectively, by weight of the composition.

### Claim 20 (depends on 18)

The pharmaceutical composition in solid unit dosage form according to claim 18 wherein microcrystalline cellulose, pregelatinized starch, magnesium stearate, calcium carbonate and sodium starch glycolate are present in amounts of about 36.5%, 31.0%, 0.5%, 15.6%, and 5.6%, respectively, by weight of the composition.

### Claim 21 (depends on 18)

The pharmaceutical composition in solid unit dosage form according to claim 18 wherein microcrystalline cellulose, pregelatinized starch, magnesium stearate, calcium carbonate and sodium search glycolate are present in amounts of about 21.1%, 30.0%, 0.75%, 15.6%, and 10.0%, respectively, by weight of the composition.

### Claim 22 (depends on 7)

The pharmaceutical composition in solid unit dosage form according to claim 7 wherein said inert ingredients comprise croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, and magnesium stearate.

### Claim 23 (depends on 22)

The pharmaceutical composition in solid unit dosage form according to claim 22 wherein croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, and magnesium stearate are present in amounts of about 1% to about 10%, 20% to about 85%, 5% to about 50% and 0.05% to about 3%, respectively, by weight of the composition.

### Claim 24 (depends on 22)

The pharmaceutical composition in solid unit dosage form according to claim 22 wherein croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, and magnesium stearate are present in amounts of about 6%, 33.3%, 30% and 0.75%, respectively, by weight of the composition.

### Claim 25 (depends on 10, 13, 16, 17, 20, 21, 24)

The pharmaceutical composition in solid unit dosage form as in either claims 10, 13, 16, 17, 20, 21 or 24 wherein said piperidinoalkanol compound is 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid hydrochloride.

### Claim 26 (depends on 25)

The pharmaceutical composition in solid unit dosage form according to claim 25 wherein 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid hydrochloride is present in an amount of about 5 mg to about 180 mg.

### Claim 27

A pharmaceutical composition prepared by a wet granulation process comprising, preparing the wet granulation wherein a compound of formula; 11
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, a diluent and a disintegrant are mixed with a solution of a binding agent; the wet granulation is screened, the wet granulation is dried, and the dry granulation is screened.

### Claim 28

A pharmaceutical composition prepared by a wet granulation process comprising, preparing the wet granulation wherein a compound of formula; 12
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, a diluent and a disintegrant are mixed with a solution of a binding agent; the wet granulation is screened, the wet granulation is dried and the dry granulation is combined with a lubricant.

### Claim 29

A pharmaceutical composition in solid unit dosage form prepared by a process comprising, blending together a compound of the formula; 13
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, lactose and pregelatinized starch; adding a solution of gelatin in water with mixing; drying and milling the mixture; and adding croscarmellose sodium with mixing.

### Claim 30 (depends on 29)

A pharmaceutical composition in solid unit dosage form according to claim 29 wherein the resulting mixture is filled into capsules.

### Claim 31 (depends on 29)

A pharmaceutical composition in solid unit dosage form according to claim 29 wherein the microcrystalline cellulose, lactose, pregelatinized starch, gelatin and croscarmellose sodium are combined in amounts of about 33.8%, 33.8%, 9.6%, 3.5% and 4.8%, respectively, by weight of the composition.

### Claim 32 (depends on 29)

A pharmaceutical composition in solid unit dosage form according to claim 29 wherein the microcrystalline cellulose, lactose, pregelatinized starch, gelatin, croscarmellose sodium and magnesium stearate are combined in amounts of about 33.7%, 33.7%, 9.6%, 3.5%, 4.8% and 0.5%, respectively, by weight of the composition.

### Claim 33

A pharmaceutical composition in solid unit dosage form prepared by a process comprising blending together a compound of the formula; 14
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, lactose and pregelatinized starch; adding a solution of gelatin in water with mixing; drying and milling the granulated mixture; adding croscarmellose sodium with mixing; and adding magnesium stearate with mixing.

### Claim 34 (depends on 33)

A pharmaceutical composition in solid unit dosage form according to claim 33 wherein the final mixture is pressed into tablets.

### Claim 35 (depends on 33)

A pharmaceutical composition in solid unit dosage form according to claim 33 wherein the microcrystalline cellulose, lactose, pregelatinized starch, gelatin, croscarmellose sodium and magnesium stearate are combined in amounts of about 33.7%, 33.7%, 9.6%, 3.5%, 4.8% and 0.5%, respectively, by weight of the composition.

### Claim 36

A pharmaceutical composition in solid unit dosage form prepared by a process comprising blending together a compound of the formula; 15
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, calcium carbonate and pregelatinized starch; adding a solution of gelatin in water with mixing; drying the granulated mixture; adding additional microcrystalline cellulose and sodium starch glycolate with blending; and adding magnesium stearate with blending.

### Claim 37 (depends on 36)

A pharmaceutical composition in solid unit dosage form according to claim 36 wherein the final mixture is pressed into tablets.

### Claim 38 (depends on 36)

A pharmaceutical composition in solid unit dosage form according to claim 36 wherein the microcrystalline cellulose, calcium carbonate, pregelatinized starch, gelatin, sodium starch glycolate and magnesium stearate are combined in total amounts of about 34.9%, 15.6%, 29.4%, 3.3%, 5.6% and 0.5%, respectively, by weight of the composition.

### Claim 39

A pharmaceutical composition in solid unit dosage form prepared by a process comprising blending together a compound of the formula; 16
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, calcium carbonate and pregelatinized starch; adding water with mixing; drying the granulated mixture; adding additional microcrystalline cellulose and sodium starch glycolate, with blending; and adding magnesium stearate with blending.

### Claim 40 (depends on 39)

A pharmaceutical composition in solid unit dosage form according to claim 39 wherein the final mixture is pressed into tablets.

### Claim 41 (depends on 39)

A pharmaceutical composition in solid unit dosage form according to claim 39 wherein the microcrystalline cellulose, calcium carbonate, pregelatinized starch, sodium starch glycolate and magnesium stearate are combined in total amounts of about 336.5%, 15.6%, 31.0%, 5.6% and 0.5%, respectively, by weight of the composition.

### Claim 42 (depends on 16)

A pharmaceutical composition in solid form according to claim 16 wherein the final mixture is pressed into a tablet from which the quantity of compound of the formula; 17
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, dissolved in 45 minutes, is not less than 75% of label in water at about 37° C. and about 50 rpm when measured using USP Apparatus 2.

### Claim 43 (depends on 17, 21, 24)

A pharmaceutical composition in solid form according to claims 17, 21 or 24 wherein the final mixture is pressed into a tablet from which the quantity of compound of the formula; 18
wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, dissolved in 45 minutes, is not less than 75% of label in 0.001 N aqueous hydrochloric acid at about 37° C. and about 50 rpm when measured using USP Apparatus 2.
